How ‘Sturgeon’ guides the surgeon in pediatric neuro-oncology

Clicks: 5
ID: 324677
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #51 of 125 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 125 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
BACKGROUND: Central nervous system (CNS) tumors represent the leading cause of pediatric cancer-related deaths. Primary treatment often involves neurosurgical tumor resection. Accurate diagnosis is crucial to perform the best-suited extent of resection. Recently, we published Sturgeon, an AI-based validated intraoperative nanopore sequencing tool, delivering accurate methylation-based diagnoses during surgery. Although several other nanopore sequencing strategies have been described, clear evidence of clinical impact remains critically absent. Here, we report a care evaluation analyzing the impact of Sturgeon on real-time pediatric neurosurgical decision-making. METHODS: Since May 2023, a dual diagnostic neuro-oncological workflow incorporating intraoperative frozen section analyses and ultra-fast nanopore sequencing using Sturgeon has been fully implemented as standard of care at the Princess Máxima Center for Pediatric Oncology in the Netherlands. This intraoperative diagnostic workflow has been applied to all pediatric patients (<19 years of age) with primary CNS tumors and the multidisciplinary indication for tumor resection surgery. RESULTS: Sturgeon delivered correct diagnoses in 82 out of 94 consecutive patients (87.2%, <90 minutes), no diagnosis in 11.7% and one incorrect diagnosis (1.1%). The diagnosis obtained by Sturgeon supported the intended surgical strategy (85.7%) or changed the strategy (14.3%) toward a more aggressive or limited resection. This contributed to a low complication rate and less second-look surgeries. Earlier communication of the histomolecular diagnosis to patients and their families was observed. CONCLUSIONS: Intraoperative use of Sturgeon provides essential guidance toward the most optimal neurosurgical strategy for pediatric CNS tumors and thereby has great potential to contribute to better clinical outcome.
Reference Key
openalex_W7202184186 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mariska Sie, O. H. J. Eelkman Rooda, Mariëtte E G Kranendonk, Pieter Wesseling, Marc Pagès-Gallego, Lennart Kester, Marc van Tuil, Eric Strengman, Janneke Slijkoort-Blom, Eugène T P Verwiel, Arie Maat, Jasper van der Lugt, Jeroen de Ridder, Bastiaan B J Tops, Carlo Vermeulen, Eelco W Hoving
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag187
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.